flow semaglutide clinical trial Effects of with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the New Science Suggests Semaglutide Improves

August 9th, 2025: Lawsuits Mount Over Vision Loss Risks Linked to Ozempic, Wegovy, and Mounjaro New research has suggested a possible connection between GLP-1 receptor agonist drugsincluding Ozempic, Wegovy, and Mounjaroand heightened risks of severe eye conditions such as neovascular age-related macular degeneration (nAMD) and nonarteritic anterior ischemic optic neuropathy (NAION)

Although their primary clinical benefits include glucose-dependent insulin secretion and appetite regulation, growing evidence indicates a wider spectrum of metabolic effects that extend beyond glycemic control [4,5,6,7]

The medication worked

Other studies, however, show that genetic loss of either GIPR or GLP-1R does not enhance the insulin response to and plasma concentrations of the alternate incretin after oral glucose administration [[1026], [1027], [1028]]

Plans that do cover weight loss medications may not cover Saxenda specifically